Phase I Trial of CCI-779 (Temsirolimus) and Weekly Bortezomib in Relapsed and/or Refractory Multiple Myeloma.

被引：0
|
作者：
Ghobrial, Irene M. [1 ]
Munshi, Nikhil [1 ]
Schlossman, Robert [1 ]
Chuma, Stacey [1 ]
Leduc, Renee [1 ]
Nelson, Marybeth [1 ]
Sam, Amy [1 ]
O'Connor, Kelly [1 ]
Harris, Brianna [1 ]
Warren, Diane [1 ]
Dollard, Akari M. [2 ]
Laubach, Jacob [1 ]
Vij, Ravi [3 ]
Campagnaro, Erica [4 ]
Birner, Ann [5 ]
Dixon-Lipscomb, Virginia
Anderson, Kenneth C. [1 ]
Richardson, Paul G. [1 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] MMRC, Norwalk, CT USA
[3] Washington Univ, St Louis, MO USA
[4] Univ Michigan, Ann Arbor, MI 48109 USA
[5] Millennium Pharmaceut Inc, Cambridge, MA USA
来源：
BLOOD | 2008年 / 112卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1266 / 1266
页数：1
相关论文
共 50 条
  • [21] Phase Ib venetoclax combined with bortezomib and dexamethasone in relapsed/refractory multiple myeloma.
    Moreau, Philippe
    Chanan-Khan, Asher Alban Akmal
    Roberts, Andrew Warwick
    Agarwal, Amit
    Facon, Thierry
    Kumar, Shaji
    Touzeau, Cyrille
    Diehl, Susan
    Cordero, Jaclyn
    Ross, Jeremy A.
    Munasinghe, Wijith
    Zhu, Ming
    Salem, Ahmed H.
    Leverson, Joel
    Maciag, Paulo Cesar
    Verdugo, Maria E.
    Harrison, Simon J.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [22] Phase I venetoclax monotherapy for relapsed/refractory multiple myeloma.
    Kumar, Shaji
    Vij, Ravi
    Kaufman, Jonathan L.
    Mikhael, Joseph
    Facon, Thierry
    Pegourie, Brigitte
    Benboubker, Lotfi
    Gasparetto, Cristina
    Amiot, Martine
    Moreau, Philippe
    Diehl, Susan
    Alzate, Stefanie
    Ross, Jeremy A.
    Dunbar, Martin
    Zhu, Ming
    Agarwal, Suresh K.
    Leverson, Joel
    Maciag, Paulo Cesar
    Verdugo, Maria E.
    Touzeau, Cyrille
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [23] Activity of the mammalian target of rapamycin inhibitor temsirolimus (CCI-779) in relapsed mantle cell lymphoma
    不详
    CLINICAL LYMPHOMA, 2004, 5 (03): : 144 - 145
  • [24] Phase I/II Trial of Plerixafor and Bortezomib As a Chemosensitization Strategy in Relapsed or Relapsed/Refractory Multiple Myeloma
    Ghobrial, Irene M.
    Laubach, Jacob P.
    Shain, Kenneth H.
    Baz, Rachid
    Boswell, Erica N.
    Henrick, Patrick M.
    Azab, Abdel Kareem
    Hanlon, Courtney
    Chuma, Stacey
    Leblebjian, Houry
    Noonan, Kimberly
    MacNabb, Megan H.
    Warren, Diane
    Armand, Philippe
    Paba-Prada, Claudia E.
    Munshi, Nikhil C.
    Schlossman, Robert L.
    Anderson, Kenneth C.
    Richardson, Paul G.
    BLOOD, 2014, 124 (21)
  • [25] Phase I study of bortezomib and 153Sm-Lexidronam combination for refractory and relapsed multiple myeloma.
    Berenson, James R.
    Swift, Regina A.
    Mapes, Russell
    Abaya, Christina D.
    BLOOD, 2006, 108 (11) : 1011A - 1012A
  • [26] Phase I/II Trial of Plerixafor and Bortezomib As a Chemosensitization Strategy In Relapsed Or Relapsed/Refractory Multiple Myeloma
    Ghobrial, Irene M.
    Shain, Kenneth
    Hanlon, Courtney
    Banwait, Ranjit
    Azab, Abdel Kareem
    Laubach, Jacob P.
    Armand, Philippe
    Munshi, Nikhil C.
    Schlossman, Robert L.
    Chuma, Stacey
    Boswell, Erica N.
    Mostyn, Patrick
    Houry, Leblebjian
    Anderson, Kenneth C.
    Richardson, Paul G.
    BLOOD, 2013, 122 (21)
  • [27] Phase I study of bortezomib and 153Sm-lexidronam combination for refractory and relapsed multiple myeloma.
    Yeh, H. S.
    Swift, R. A.
    Ferretti, D.
    Mapes, R. A.
    Goeckeler, W. F.
    Berenson, J. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 450S - 450S
  • [28] Phase I/II study of bortezomib in combination with liposomal doxorubicin and melphalan in relapsed or refractory multiple myeloma.
    Chari, A
    Kaplan, L
    Linker, C
    Damon, LE
    Navarro, WH
    Martin, T
    BLOOD, 2005, 106 (11) : 379B - 379B
  • [29] Bendamustine-bortezomib-dexamethasone in relapsed/refractory multiple myeloma.
    Cerchione, Claudio
    Nappi, Davide
    Cangini, Delia
    Ronconi, Sonia
    Ceccolini, Michela
    Musuraca, Gerardo
    Martinelli, Giovanni
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [30] A phase I/II trial evaluating the combination of arsenic trioxide, bortezomib and ascorbic acid for patients with relapsed or refractory multiple myeloma.
    Berenson, J
    Matous, J
    Ferretti, D
    Swift, R
    Mapes, R
    Morrison, B
    Yeh, H
    Bevivino, S
    BLOOD, 2005, 106 (11) : 721A - 721A
12345